ArrowheadPharma's banner
ArrowheadPharma's profile picture

ArrowheadPharma

@ArrowheadPharma • 3,855 subscribers

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Shorts

Breaking News: We’re pleased to announce positive topline results, with our Phase 3 SHASTA-3 and SHASTA-4 studies achieving the primary endpoint and all secondary endpoints in patients living with severe hypertriglyceridemia (sHTG).​ Learn more:

Breaking News: We’re pleased to announce positive topline results, with our Phase 3 SHASTA-3 and SHASTA-4 studies achieving the primary endpoint and all secondary endpoints in patients living with severe hypertriglyceridemia (sHTG).​ Learn more:

21,564 Aufrufe

We’ve entered a strategic partnership with Madrigal Pharmaceuticals to advance an RNAi therapeutic for MASH, combining the precision of Arrowhead’s TRiM™ platform with Madrigal’s liver disease expertise. Read the full announcement:

We’ve entered a strategic partnership with Madrigal Pharmaceuticals to advance an RNAi therapeutic for MASH, combining the precision of Arrowhead’s TRiM™ platform with Madrigal’s liver disease expertise. Read the full announcement:

14,563 Aufrufe

🚨 FDA APPROVED! Arrowhead’s therapy to lower triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) offers new hope for patients & families facing this #RareDisease. A major step forward in RNAi innovation. #FCS #FDAApproval

🚨 FDA APPROVED! Arrowhead’s therapy to lower triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) offers new hope for patients & families facing this #RareDisease. A major step forward in RNAi innovation. #FCS #FDAApproval

18,539 Aufrufe